Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2020 Earnings Conference Call - Final Transcript
Jul 31, 2020 • 05:30 am ET
towards our deleveraging target. We ended quarter one with net debt to adjusted EBITDA of 3.7 times and we remain confident to reach 2 times within the fiscal years 2021 to 2023 time frame.
Before we start the Q&A session, I'd like to draw your attention to Slide 39 where we list some upcoming investor events. In particular, we are planning an event in the second half of fiscal year where we will provide further details on the market potential of our Wave 1 pipeline and why we believe in its potential to deliver over $10 billion in peak revenue.
Thank you for your attention. And now we'll move to Q&A.